These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20499349)

  • 1. Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.
    Grey A; Bolland M; Wattie D; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2010 Oct; 25(10):2251-5. PubMed ID: 20499349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
    Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
    Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.
    Grey A; Bolland MJ; Wattie D; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2009 Feb; 94(2):538-44. PubMed ID: 19050050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Callon KE; Gamble GD; Reid IR
    J Bone Miner Res; 2008 Aug; 23(8):1304-8. PubMed ID: 18627266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
    Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
    CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
    Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone turnover 18 months after a single intravenous dose of zoledronic acid.
    Borba VZ; Paz-Filho G; Kulak CA; Seibel MJ; Bilezikian JP
    Int J Clin Pract; 2007 Jun; 61(6):1058-62. PubMed ID: 17504370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial.
    Dalbeth N; Aati O; Gamble GD; Horne A; House ME; Roger M; Doyle AJ; Chhana A; McQueen FM; Reid IR
    Ann Rheum Dis; 2014 Jun; 73(6):1044-51. PubMed ID: 24442886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
    Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.